按脑转移数目分层的EGFR突变非小细胞肺癌脑转移患者局部治疗与EGFR-TKI的最佳顺序
该单中心回顾性研究纳入176例EGFR突变非小细胞肺癌脑转移患者,按先行EGFR-TKI或先行局部治疗分组并按脑转移数目分层。总体上两组总生存无显著差异;在1至4个脑转移患者中,先行局部治疗组总生存显著优于先行TKI组。
要点
- 176例中61%先行EGFR-TKI、39%先行局部治疗,1至4个脑转移者两组比例相似(56% vs 52%;P = .61)。
- 1至4个脑转移患者中,先行局部治疗组中位总生存35个月 vs 先行TKI组23个月(HR 0.54;95%CI 0.32-0.90)。
- ≥5个脑转移患者中先行局部治疗与先行TKI的总生存无差异,多变量分析显示1至4个脑转移者先行局部治疗总生存显著更优。
核心结论
- 对携带EGFR突变、有1至4个脑转移的未治疗患者,先行局部治疗后续EGFR-TKI较先行EGFR-TKI对生存更有效。
研究设计与样本
- 单中心回顾性研究,纳入176例EGFR突变非小细胞肺癌脑转移患者,按先行治疗分为EGFR-TKI组(61%)与局部治疗组(39%),并按脑转移数目分层。
主要发现
- 1至4个脑转移患者比例在两组相似(56% vs 52%;P = .61)。
- 局部治疗组中1至4个脑转移者除手术病例外均接受立体定向放射外科(n = 31)。
- ≥5个脑转移者中多数(n = 27;82%)接受全脑放射治疗。
- 局部治疗组与TKI组总生存无显著差异(中位总生存28 vs 23个月;HR 0.75;95%CI 0.52-1.07)。
- 1至4个脑转移患者中,局部治疗组总生存显著优于TKI组(中位总生存35 vs 23个月;HR 0.54;95%CI 0.32-0.90);≥5个脑转移者两组总生存无差异。
临床怎么用
- 作者结论认为,对携带EGFR突变、有1至4个脑转移的未治疗患者,先行局部治疗后续EGFR-TKI较先行EGFR-TKI对生存更有效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: It is unclear whether local therapy (LT) or epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) should take precedence for patients with EGFR-mutant non-small cell lung cancer (NSCLC) and brain metastases (BMs). The number of BMs is important in the choice of LT, including whole-brain radiation therapy, stereotactic radiosurgery, and surgery. METHODS: We retrospectively evaluated cases of EGFR-mutant non-small cell lung cancer with BMs from a single site. Patients were divided into 2 groups based on upfront therapy-EGFR-TKI (TKI) or LTs-and subsequently stratified by the number of BMs. RESULTS: Among 176 patients, 61% received upfront EGFR-TKI, and 39% received upfront LT. The number of patients with 1 to 4 BMs was similar (56% vs 52%; P = .61). All patients with 1 to 4 BMs in the LT group, except for surgical cases, received stereotactic radiosurgery (n = 31). Among those with ≥5 BMs, most (n = 27; 82%) received whole-brain radiation therapy. There was no significant difference in OS between LT and TKI groups (median overall survival, 28 vs 23 months; hazard ratio, 0.75; 95% confidence interval, 0.52-1.07). In patients with 1 to 4 BMs, the LT group showed significantly better OS compared with the TKI group (median overall survival, 35 vs 23 months; hazard ratio, 0.54; 95% confidence interval, 0.32-0.90). There was no difference in OS between the LT and TKI groups for patients with ≥5 BMs. Multivariable analysis showed that upfront LT yielded significantly better OS for patients with 1 to 4 BMs. CONCLUSION: Upfront LT followed by EGFR-TKI is more effective than upfront EGFR-TKI for the survival of untreated patients harboring EGFR mutations with 1 to 4 BMs.
引用
- Miyawaki E, Kenmotsu H, Mori K, et al. Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases. Int J Radiat Oncol Biol Phys. 2019. PMID: 30851347. doi:10.1016/j.ijrobp.2019.02.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。